IRWD Q2 2024 Earnings — Ironwood Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IRWDIronwood Pharmaceuticals, Inc.

$629M

Q2 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$94M-12.1% YoY

Gross Profit

$94M100.0% margin

Operating Income

$25M26.5% margin

Net Income

-$860,000-0.9% margin

EPS (Diluted)

$-0.01

QoQ Revenue Growth

+26.1%

Cash Flow

Operating Cash Flow

$33M

Free Cash Flow

$33M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$396M

Total Liabilities

$717M

Stockholders' Equity

-$322M

Cash & Equivalents

$106M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$94M	$107M	-12.1%
Gross Profit	$94M	$88M	+7.8%
Operating Income	$25M	-$1.1B	+102.3%
Net Income	-$860,000	-$1.1B	+99.9%

Revenue Segments

Collaborative arrangement, collaboration and license agreements

$419,00043%

Collaborative arrangement, other agreements

$358,00037%

Royalty

$200,00020%

Geographic Segments

North America

$92M99%

Europe and Other

$833,0001%